Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 22 for:    BMS-986016

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04150965
Recruitment Status : Not yet recruiting
First Posted : November 5, 2019
Last Update Posted : March 24, 2020
Sponsor:
Collaborators:
Bristol-Myers Squibb
Emory University
Washington University School of Medicine
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Atrium Health
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai
University of Texas
University of California, San Francisco
Information provided by (Responsible Party):
Multiple Myeloma Research Consortium

Brief Summary:

This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles.

A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.


Condition or disease Intervention/treatment Phase
Multiple Myeloma Relapsed Refractory Multiple Myeloma Drug: Elotuzumab, pomalidomide, dexamethasone Drug: Anti-LAG-3 Drug: Anti-LAG-3 + Pomalidimide + Dexamethasone Drug: Anti-TIGIT Drug: Anti-TIGIT + Pomalidimide + Dexamethasone Phase 1 Phase 2

Detailed Description:

This study will enroll 104 patients to one of three treatment arms. The study is open to patients relapsing with refractory Multiple Myeloma who have:

  • received 3 prior lines of therapy
  • exposed to each of these 3 drug classes:

    • IMiD
    • proteasome inhibitors, and
    • anti-CD38 monoclonal antibody
  • relapsed and refractory are defined using the IMWG criteria:

    • disease that is non-responsive while on salvage therapy or progresses within 60 days of last therapy in patients who have achieved minimal response or better at some point previously to then progressing in their disease course.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Arm B: Anti-LAG-3 will treat patients with single agent for Cycle 1. In Cycle 2 and beyond Arm B combination Anti-LAG-3 + Pomalidomide + Dexamethasone.

Arm C: Anti-TIGIT will treat patients with single agent for Cycle 1. In Cycle 2 and beyond Arm C combination Anti-TIGIT + Pomalidomide + Dexamethasone.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)
Estimated Study Start Date : April 15, 2020
Estimated Primary Completion Date : March 1, 2022
Estimated Study Completion Date : March 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Elotuzumab

Arm Intervention/treatment
Active Comparator: Arm A - Elotuzumab
Patients receive Elotuzumab in combination with pomalidomide and dexamethasone. Arm A begings in Phase 2 portion.
Drug: Elotuzumab, pomalidomide, dexamethasone
Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
Other Name: Empliciti

Experimental: Arm B - Anti LAG-3 Single Agent
Patients receive Anti-LAG-3 as a single agent for 1 Cycle in Phase 1 portion.
Drug: Anti-LAG-3

Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days

Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long.

Other Names:
  • BMS-986016
  • Anti LAG-3
  • Relatlimab

Experimental: Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone
Cycle 2 and beyond Patients receive Anti-LAG-3 in combination with pomalidomide and dexamethasone.
Drug: Anti-LAG-3 + Pomalidimide + Dexamethasone
Patients with Relapsed & Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
Other Names:
  • BMS-986016
  • Anti-LAG-3, Pomalidomide, Dexamethasone

Experimental: Arm C - Anti-TIGIT Single Agent
Patients receive Anti-TIGIT as a single agent for 1 Cycle in Phase 1 portion.
Drug: Anti-TIGIT

Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.

Each cycle is 28 days.

Other Name: BMS-986207

Experimental: ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone
Cycle 2 and beyond Patients receive Anti-TIGIT in combination with pomalidomide and dexamethasone.
Drug: Anti-TIGIT + Pomalidimide + Dexamethasone
Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
Other Name: BMS-986207




Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 18 months. ]
    The overall response rate of the drug combination, in each Arm for RRMM, which is defined as the proportion of subjects who achieved a response (≥ VGPR).

  2. Frequency, type and grade of Adverse Events and Serious Adverse Events [ Time Frame: Cycle 1 (28 days) ]
    Frequency, type and grade of Adverse Events and Serious Adverse Events during Cycle 1 of Single agent Arms B and C. In Combination for all Arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 years of age or greater.
  2. Willing and able to provide informed consent
  3. Patient has received at least 3 prior lines of therapy and must have received prior therapy including at least one drug from each drug class; IMiD, proteasome inhibitors, and anti-CD38 monoclonal antibody.
  4. The following laboratory values obtained ≤ 14 days prior to initiation of therapy:

    1. ANC ≥ 1000/ul (without growth factor support within 14 days of initiation of therapy)
    2. Hgb ≥ 8 g/dl
    3. PLT ≥ 75,000/ul (without transfusion support within 14 days of initiation of therapy)
    4. Total bilirubin <1.5 x upper limit of normal (ULN) or if total bilirubin is >1.5 x ULN, the direct bilirubin must be ≤ 2.0 mg/dL (patients with Gilberts syndrome may have total bilirubin ≤3.0 x ULN
    5. AST and AST < 2.5x ULN
    6. Creatinine Clearance ≥ 30 mL/min by Cockcroft Gault Equation
  5. Measurable disease of MM as defined by at least ONE of the following:

    1. Serum monoclonal protein ≥1.0 g by protein electrophoresis
    2. ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis
    3. Serum immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio.
  6. Normal thyroid function, or stable on hormone supplementation per investigator assessment.
  7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2.
  8. Willingness to return to enrolling institution for follow-up.
  9. Disease free of prior malignancies for ≥ 3 year with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma "insitu" of the cervix or breast, or prostate cancer not requiring therapy
  10. Ability to understand the purpose and risks of the study and provide signed and dated ICF and authorization to use protected health information.
  11. All study participants must be willing to be registered into, and comply with, the mandatory pomalidomide (POMALYST®) Risk Evaluation and Mitigation Strategy (REMS®) program and be willing to use contraception 28 days prior to pomalidomide treatment and continue until 120 days after the last dose of pomalidomide.
  12. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin).
  13. All females of child bearing potential (FCBP)* must have a negative pregnancy test (urine or serum) documented ≤7 days prior to start of therapy with repeat pregnancy test on Day 1 of each cycle and at the EoT visit. Note: Additional pregnancy testing is required as a condition of the POMALYST REMS® program prior to and while on treatment and following the last dose of pomalidomide. FCBP must have 2 negative pregnancy tests prior to initiating pomalidomide treatment. The first test should be performed within 10-14 days prior to prescribing POMALYST and the second test within 24 hours prior to prescribing POMALYST therapy and then weekly during the first 4 weeks, then every 4 weeks thereafter in females with regular menstrual cycles, or every 2 weeks in females with irregular menstrual cycles. Protocol section 8.1 provides guidelines on the use and required time frames of contraception. NOTE: *A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Exclusion Criteria:

  1. Patient is known to be human immunodeficiency virus (HIV) positive, Hepatitis B surface antigen-positive, or active Hepatitis C infection;
  2. Pregnant or breast feeding females;
  3. Any clinically significant, uncontrolled medical conditions including, but not limited to, myocardial infarction or stroke/transient ischemic attack within the past 6 months, uncontrolled angina within the past 3 months, symptomatic congestive heart failure, cardiac arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), pericarditis, myocarditis, cardiomyopathy, requirement for supplemental oxygen;
  4. Any psychiatric illness/social situations that, in the Investigator's opinion, would impose excessive risk to the patient or may interfere with compliance or interpretation of the study results;
  5. QT interval corrected for heart rate using Fridericia's formula (QTcF) prolongation > 480 msec, except for right bundle branch block;
  6. Ongoing or active infection, that requires systemic antibacterial, antiviral, or antifungal therapy < 7 days prior to the initiation of therapy
  7. Inability to tolerate thromboprophylaxis ;
  8. Known CNS involvement;
  9. Known severe intolerance to steroid therapy (Grade 3 or above adverse event unresponsive to dose reduction and/or per investigators discretion);
  10. History of autoimmune disease, requiring therapy including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, glomerulonephritis, or suspected autoimmune disease. (Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, euthyroid with a history of Grave's disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating Ig prior to the first dose of study drug), psoriasis not requiring systemic treatment, well controlled asthma and/or mild allergic rhinitis [seasonal allergies], or conditions not expected to recur in the absence of an external trigger);
  11. NYHA Classification > Class 2;
  12. Concurrent amyloidosis, plasma cell leukemia or POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes;
  13. History of erythema multiforme or severe (≥ grade 3) hypersensitivity to prior IMiD's;
  14. Anti-cancer therapy within the specified time frames prior to initiation of therapy:

    cytotoxic investigational agents, within 3 weeks (6 weeks for nitrosoureas), IMiDs, Proteosome inhibitors or corticosteroids within 2 weeks, investigational therapies within 14 days or 5 half-lives of the investigational drug, whichever is longer, and monoclonal antibodies within 4 weeks. Prednisone up to but no more than 10 mg orally q.d. or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days. Live vaccines within 30 days (The inactivated seasonal influenza vaccine can be given to patients before treatment and while on therapy without restriction). Shorter time lines may be considered in consultation with the PI;

  15. Prior major surgery or radiation therapy within 4 weeks of initiation of therapy;
  16. Prior therapy with Anti-TIGIT or Anti-LAG-3 ;
  17. Any > Grade 1 adverse reaction unresolved from previous treatments according to the NCI CTC AE v 5.0. The presence of alopecia or peripheral neuropathy ≤ Grade 2 without pain is allowed;
  18. Previous allogeneic stem cell transplantation;
  19. Immunosuppressive therapy in the last 2 months prior to initiation of therapy;
  20. Autologous stem cell transplant if < 12 weeks from initiation of therapy;
  21. History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.);
  22. Cardiac Troponin T (cTnT) or I(cTnI)≥2×institutional ULN.

    1. Subjects with cTnT or cTnI levels between > 1 to 2 × ULN will be permitted if repeat levels within 24 hours are ≤ 1 ULN
    2. If cTnT or cTnI levels are >1 ULN at 24 hours, the subject may undergo a cardiac evaluation and be considered for treatment, following a discussion with the Principal Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04150965


Contacts
Layout table for location contacts
Contact: MMRF Patient Support Center, RN 888-841-6673 patientnavigator@themmrf.org

Locations
Layout table for location information
United States, California
University of California San Francisco
San Francisco, California, United States, 94143
Contact: Jeffrey Wolf, M.D.         
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Contact: Madhav V. Dhodapkar, M.D.         
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Contact: David Avigan, M.D.         
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Contact: Giada Bianchi, M.D.         
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Contact: Taxiarchis Kourelis, M.D.         
United States, Missouri
Washington University School of Medicine Division of Medical Oncology
Saint Louis, Missouri, United States, 63110
Contact: Ravi Vij, M.D.         
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
Contact: Shambavi Richard, M.D.         
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Contact: Alex Lesokhin, M.D.         
United States, North Carolina
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Contact: Barry Paul, M.D.         
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Contact: Ankit Kansagra, M.D.         
Sponsors and Collaborators
Multiple Myeloma Research Consortium
Bristol-Myers Squibb
Emory University
Washington University School of Medicine
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Atrium Health
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai
University of Texas
University of California, San Francisco
Layout table for additonal information
Responsible Party: Multiple Myeloma Research Consortium
ClinicalTrials.gov Identifier: NCT04150965    
Other Study ID Numbers: MyCheckpoint (MMRC-089)
First Posted: November 5, 2019    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Multiple Myeloma Research Consortium:
Multiple Myeloma
Relapsed
Refractory
MM
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
MMRC
MMRF
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Thalidomide
Dexamethasone
Dexamethasone acetate
Pomalidomide
Elotuzumab
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal